75 results
424B3
EVOK
Evoke Pharma Inc
14 Mar 24
Prospectus supplement
6:44pm
with the Minimum Stockholders’ Equity Requirement to the satisfaction of Nasdaq currently or in any future periods, even applying the proceeds from the February 2024 … and the satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations since
8-K
EX-4.1
EVOK
Evoke Pharma Inc
14 Feb 24
Unregistered Sales of Equity Securities
9:00am
(in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction
8-K
ln8np6rw hayjr
14 Feb 24
Unregistered Sales of Equity Securities
9:00am
8-K
EX-99.1
dpaxj
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
8-K
mk2v 073omd2h
9 Feb 24
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
5:15pm
424B4
ajsffvs4to5w e7jwokd
9 Feb 24
Prospectus supplement with pricing info
5:14pm